Evidence map›Paper›PMID 38806647›Full record

ArticleNature cell biology2024

Maintenance of R-loop structures by phosphorylated hTERT preserves genome integrity.

Mitsuhiro Machitani, Akira Nomura, Taro Yamashita, Mami Yasukawa, Saori Ueki, Ken-Ichi Fujita, Toshihide Ueno, Akio Yamashita, Yoshikazu Tanzawa, Masahiko Watanabe and 6 more

Erratum issuedAbstract read
PubMed Publisher
In one paragraph

Article in Nature cell biology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Review
  2. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

16 authors.

Mitsuhiro Machitani *Division of Cancer Stem Cell, National Cancer Center Research Institute, Tokyo, Japan.ORCID http://orcid.org/0009-0007-0783-1885
Akira Nomura *Division of Cancer Stem Cell, National Cancer Center Research Institute, Tokyo, Japan.ORCID http://orcid.org/0000-0002-8627-0620
Taro YamashitaDepartment of Gastroenterology, Kanazawa University Graduate School of Medical Sciences, Kanazawa, Japan.ORCID http://orcid.org/0000-0002-3383-9131
Mami YasukawaDivision of Cancer Stem Cell, National Cancer Center Research Institute, Tokyo, Japan.ORCID http://orcid.org/0000-0002-4214-8922
Saori UekiDivision of Cancer Stem Cell, National Cancer Center Research Institute, Tokyo, Japan.
Ken-Ichi FujitaDivision of Cancer Stem Cell, National Cancer Center Research Institute, Tokyo, Japan.
Toshihide UenoDivision of Cellular Signaling, National Cancer Center Research Institute, Tokyo, Japan.ORCID http://orcid.org/0000-0002-7408-7298
Akio YamashitaDepartment of Investigative Medicine, University of the Ryukyus Graduate School of Medicine, Nakagami, Japan.ORCID http://orcid.org/0000-0001-7095-4473
Yoshikazu TanzawaDepartment of Orthopaedic Surgery, Surgical Science, Tokai University School of Medicine, Isehara, Japan.
Masahiko WatanabeDepartment of Orthopaedic Surgery, Surgical Science, Tokai University School of Medicine, Isehara, Japan.ORCID http://orcid.org/0000-0001-9038-0446
Toshiyasu TaniguchiDepartment of Molecular Life Science, Tokai University School of Medicine, Isehara, Japan.
Noriko SaitohDivision of Cancer Biology, The Cancer Institute of JFCR, Tokyo, Japan.ORCID http://orcid.org/0000-0002-2601-2806
Shuichi KanekoDepartment of Gastroenterology, Kanazawa University Graduate School of Medical Sciences, Kanazawa, Japan.ORCID http://orcid.org/0000-0001-7113-3319
Yukinari KatoDepartment of Antibody Drug Development, Tohoku University Graduate School of Medicine, Sendai, Japan.ORCID http://orcid.org/0000-0001-5385-8201
Hiroyuki ManoDivision of Cellular Signaling, National Cancer Center Research Institute, Tokyo, Japan.ORCID http://orcid.org/0000-0003-4645-0181
Kenkichi MasutomiDivision of Cancer Stem Cell, National Cancer Center Research Institute, Tokyo, Japan. kmasutom@ncc.go.jp.ORCID http://orcid.org/0000-0002-6739-4257

Funding

Japan Agency for Medical Research and Development (AMED) JP20ck0106403Japan Agency for Medical Research and Development (AMED) JP21cm0106115Japan Agency for Medical Research and Development (AMED) JP21cm0106584Japan Agency for Medical Research and Development (AMED) JP22ama121008Japan Agency for Medical Research and Development (AMED) JP24ym0126804MEXT | Japan Science and Technology Agency (JST) JPMJMS2022MEXT | Japan Society for the Promotion of Science (JSPS) 20H03438MEXT | Japan Society for the Promotion of Science (JSPS) 22K15550
6 · The paper itself

Abstract

As aberrant accumulation of RNA-DNA hybrids (R-loops) causes DNA damage and genome instability, cells express regulators of R-loop structures. Here we report that RNA-dependent RNA polymerase (RdRP) activity of human telomerase reverse transcriptase (hTERT) regulates R-loop formation. We found that the phosphorylated form of hTERT (p-hTERT) exhibits RdRP activity in nuclear speckles both in telomerase-positive cells and telomerase-negative cells with alternative lengthening of telomeres (ALT) activity. The p-hTERT did not associate with telomerase RNA component in nuclear speckles but, instead, with TERRA RNAs to resolve R-loops. Targeting of the TERT gene in ALT cells ablated RdRP activity and impaired tumour growth. Using a genome-scale CRISPR loss-of-function screen, we identified Fanconi anaemia/BRCA genes as synthetic lethal partners of hTERT RdRP. Inactivation of RdRP and Fanconi anaemia/BRCA genes caused accumulation of R-loop structures and DNA damage. These findings indicate that RdRP activity of p-hTERT guards against genome instability by removing R-loop structures.

Indexed as

DNA DamageGenomic InstabilityR-Loop StructuresTelomeraseTelomere HomeostasisAnimalsCell Line, TumorHEK293 CellsHumansPhosphorylationRNATelomereRNATelomerasetelomerase RNATERT protein, human

Identifiers

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.